Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30

$18.89−0.84 (-4.26%)

Close on Nov 12, 2026Market cap $3.02BP/E –Yield –

Denali Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q2 FY2026	Jun 30, 2026	97.4%	–

Parsed from the XBRL in Denali Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DNLI.

Advertisement
300 × 250

See a number that looks wrong?